×
About 298 results

ALLMedicine™ Cold Agglutinin Disease Center

Research & Reviews  104 results

Bone marrow and peripheral blood involvement of relapsed diffuse large B-cell lymphoma ...
https://doi.org/10.1111/ijlh.13860
International Journal of Laboratory Hematology; Chang SH

May 17th, 2022 - The author report an interesting case of relapsed diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) and peripheral blood (PB) involvement after prior cold agglutinin disease (CAD). A minority of patients with DLBCL present with CAD, and ...

A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease
https://clinicaltrials.gov/ct2/show/NCT04269551

May 2nd, 2022 - Up to 23 weeks (screening period up to 8 weeks, treatment period 15 weeks)

Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058691
BMJ Case Reports; Dawudi Y, Federici L et. al.

Apr 30th, 2022 - Impaired immune response with uncontrolled inflammation and various immunological disorders have been reported during SARS-CoV-2 infection. Here, we report a case of cold agglutinin disease occurring during a severe coronavirus disease 2019 (COVID...

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)
https://clinicaltrials.gov/ct2/show/NCT03347396

Apr 25th, 2022 - The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=) 2 gram per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increases Hgb to >= 12 g/dL and obviates the need for blood trans...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  3 results

A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease
https://clinicaltrials.gov/ct2/show/NCT04269551

May 2nd, 2022 - Up to 23 weeks (screening period up to 8 weeks, treatment period 15 weeks)

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)
https://clinicaltrials.gov/ct2/show/NCT03347396

Apr 25th, 2022 - The purpose of Part A is to determine whether sutimlimab administration results in a greater than or equal to (>=) 2 gram per deciliter (g/dL) increase in hemoglobin (Hgb) levels or increases Hgb to >= 12 g/dL and obviates the need for blood trans...

Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
https://clinicaltrials.gov/ct2/show/NCT01696474

Oct 27th, 2017 - Based on its activity in MM, single agent Bortezomib was tested in phase II trials in lymphoplasmacytic lymphoma, the disorder most frequently associated with CAD, and achieved 40-80% responses. These striking clinical responses indicate that prot...

see more →

News  11 results

Experimental Agents for ITP
https://www.onclive.com/view/experimental-agents-for-itp

Feb 23rd, 2022 - Craig Kessler, MD: Sutimlimab is a humanized monoclonal antibody that selectively inhibits activation of the complement pathway by binding to complement 1S. This drug, which is not approved, will be marketed by Sanofi. It was originally developed ...

Old Drug, New Cancer Tricks? No Need to Delay Mammo; 'CeMe' Cervical Cancer Campaign
https://www.medpagetoday.com/hematologyoncology/othercancers/97125

Feb 10th, 2022 - A 30-year-old investigational drug could get another look as a potential cancer therapy as a result of the growing emphasis on precision medicine. (VCU Health, Molecular Cancer Therapeutics) The Centers for Medicare & Medicaid Services expanded el...

FDA Approves First Drug for Cold Agglutinin Disease
https://www.medscape.com/viewarticle/967966

Feb 7th, 2022 - A new drug has become the first and only treatment for people with cold agglutinin disease (CAD) that is approved by the US Food and Drug Administration (FDA). CAD is a rare autoimmune hemolytic anemia, affecting about 5000 people in the United St...

Fast Five Quiz: Cold Agglutinin Disease
https://www.medscape.com/viewarticle/959368

Nov 18th, 2021 - Cold agglutinin disease (CAD) is a rare, complement-dependent, classical pathway–mediated immune hemolytic disease, accounting for up to 25% of autoimmune hemolytic anemia. Whereas the incidence of CAD is rare, the disease burden is frequently hig...

Sanofi gets priority U.S. FDA review for sutimlimab product
https://www.reuters.com/article/us-sanofi-products/sanofi-gets-priority-u-s-fda-review-for-sutimlimab-product-idUSKBN22Q0JI

May 14th, 2020 - FILE PHOTO: The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020. REUTERS/Charles Platiau PARIS (Reuters) - French healthcare company Sanofi said on Thursday that the U.S. Food & Drug Administration (FDA) regul...

see more →